SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a frontrunner in AI options for medical trials, at the moment introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm creating therapies for neurodegenerative ailments. The outcomes have been shared on the 2025 Alzheimer’s & Parkinson’s Drug Improvement Summit in Boston.
The collaboration centered on remynd’s Part 2a medical trial of REM127, an investigational, first-generation small molecule remedy focusing on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The examine enrolled a restricted variety of members and measured modifications in AD biomarkers over a brief remedy window.
Unlearn supported the examine by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin educated on information from greater than 26,000 members throughout landmark AD datasets akin to ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline information to forecast their medical and biomarker trajectories below normal care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering a further layer of proof to assist interpret modifications noticed within the handled inhabitants. This method is especially useful in early-phase research the place small pattern sizes restrict the power to attract conclusions utilizing conventional statistical strategies alone.
“This can be a highly effective instance of how digital twins will help unlock insights from small research,” stated Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to assist smarter, quicker medical analysis.”
“The collaboration with Unlearn and the ensuing information additional will increase our confidence in our pioneering method in the direction of attaining symptomatic reduction and illness modification in Alzheimer’s. This can assist our efforts to advance an optimized second-generation remedy,” stated Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins provide a brand new lens for decoding biomarker traits over time—particularly in early-stage trials the place each information level issues.”
For extra info, go to www.unlearn.ai or observe us on LinkedIn and X/Twitter.
